放射性医薬品の世界市場レポート 2025年

放射性医薬品市場規模は、今後数年で急成長が見込まれます。2029年には105億9,000万米ドルに成長し、CAGRは11.8%となります。予測期間の成長は、高齢者人口の増加、がんや心血管疾患の有病率の増加、高額の設備投資、新製品の発売などに起因しています。予測期間の主な動向としては、収益向上と製品品質向上のための他社との提携、需要増に対応するための工場能力拡張への投資、新たな需要に対応するための新技術への投資、より合理的で科学的なアプローチのためのインシリコモデリングの探求、研究開発コストの削減と医薬品開発期間の短縮のためのAIへの投資、収益向上のための循環器科に対応した技術への投資、がんの正確でタイムリーな診断のための疾患特異的アプローチの受け入れなどが挙げられます。

がんと心血管疾患の有病率の上昇は、放射性医薬品市場の需要を促進すると予想されます。放射性医薬品は、従来の医薬品と比較して安全で効果的な治療オプションとなりつつあり、これらの疾患の治療において放射線科医に利益をもたらす標的治療などの利点を提供しています。がんは世界的に第2位の死因として認識されており、約6人に1人が死亡しています。例えば、2024年4月、フランスを拠点とする専門機関である国際がん研究機関（IARC）は、2022年には世界中で約2,000万人のがん患者が新たに発生し、970万人ががんに関連して死亡したと報告しました。2040年までには、この数字は年間2,990万人の新規罹患者と1,530万人の死亡者に増加すると予測されています。

放射性医薬品市場は、個別化医療に対する需要の高まりによって大きな成長が見込まれています。個別化医療は精密医療とも呼ばれ、医療上の意思決定、治療、介入、薬物療法を患者一人ひとりの特徴に合わせて調整する医療への革新的なアプローチです。個別化医療を放射性医薬品に統合することで、画像診断や治療の精度と正確性が向上し、ヘルスケアプロバイダーはより的を絞った効果的な治療を提供できるようになります。例えば、2022年に米国食品医薬品局（FDA）の医薬品評価研究センター（CDER）は37の新規分子化合物（NME）を承認したが、そのうち約34％にあたる12が個別化医療連合（PMC）によって個別化医療に分類されました。このように、個別化医療に対する需要の高まりが、放射性医薬品市場の成長の原動力となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界放射性医薬品 PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の放射性医薬品市場：成長率分析
• 世界の放射性医薬品市場の実績：規模と成長, 2019-2024
• 世界の放射性医薬品市場の予測：規模と成長, 2024-2029, 2034F
• 世界放射性医薬品総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の放射性医薬品市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 診断
• 治療的
• 世界の放射性医薬品市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 腫瘍学
• 心臓病学
• 消化器内科
• 神経内分泌学
• 筋骨格
• 呼吸器
• 腎臓学
• その他の用途
• 世界の放射性医薬品市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院および外来手術センター
• 診断センター
• がん調査機関
• 世界の放射性医薬品市場、診断のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 陽電子放出断層撮影（PET）放射性医薬品
• 単一光子放出コンピュータ断層撮影（SPECT）放射性医薬品
• 世界の放射性医薬品市場、治療のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• アルファ放射体
• ベータ線放射体
• 近接放射線療法

第7章 地域別・国別分析

• 世界の放射性医薬品市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の放射性医薬品市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 放射性医薬品市場：競合情勢
• 放射性医薬品市場：企業プロファイル
  • Cardinal Health Overview, Products and Services, Strategy and Financial Analysis
  • Curium Pharma Overview, Products and Services, Strategy and Financial Analysis
  • Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • General Electric Company（GE）Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• IBA Group
• Bayer AG
• Lantheus Medical Imaging Inc.
• Bracco Imaging S.p.A.
• Eckert & Ziegler
• Nihon Medi-Physics Co. Ltd.
• Fujifilm Corporation
• ANSTO
• Yantai Dongcheng Pharmaceutical Group Co. Ltd.
• Bracco Imaging SpA.
• Canon Inc.
• China Isotope & Radiation Corporation（CIRC）
• Alliance Medical
• Advanced Accelerator Applications
• JSC Isotope

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 放射性医薬品市場2029：新たな機会を提供する国
• 放射性医薬品市場2029：新たな機会を提供するセグメント
• 放射性医薬品市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Radiopharmaceuticals, also known as radioactive medications, are substances used for the diagnosis or treatment of diseases, including cancer, and contain a radioactive material. These medications are employed in various medical procedures to identify specific illnesses or detect medical issues. Patients may receive radiopharmaceuticals through different administration methods, such as injection, oral ingestion, or application into the eye or bladder.

Radiopharmaceuticals can be broadly categorized into diagnostic, therapeutic, and other types. The process of delivering radioactive atoms to targets associated with tumors is known as radiopharmaceutical therapy. These medications find applications in fields such as oncology, cardiology, gastroenterology, neuroendocrinology, neurology, nephrology, and others. Hospitals, ambulatory surgical centers, diagnostic centers, cancer research institutes, and similar healthcare facilities commonly utilize radiopharmaceuticals for various medical purposes.

The radiopharmaceuticals market research report is one of a series of new reports from The Business Research Company that provides radiopharmaceuticals market statistics, including radiopharmaceuticals industry global market size, regional shares, competitors with a radiopharmaceuticals market share, detailed radiopharmaceuticals market segments, market trends and opportunities, and any further data you may need to thrive in the radiopharmaceuticals industry. This radiopharmaceuticals market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The radiopharmaceuticals market size has grown steadily in recent years. It will grow from $6.46 billion in 2024 to $6.77 billion in 2025 at a compound annual growth rate (CAGR) of 4.7%. The growth in the historic period can be attributed to rise in healthcare expenditure, government initiatives, convenience of treatment, and changes in lifestyles.

The radiopharmaceuticals market size is expected to see rapid growth in the next few years. It will grow to $10.59 billion in 2029 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to increasing geriatric population, increasing prevalence of cancer and cardiovascular diseases, high capital investments, and new product launches. Major trends in the forecast period include collaborating with other companies to boost revenues and improve product quality, investing in plant capacity expansions to cater to the increasing demand, investing in new technologies to meet the emerging demands, explore in silico modeling for a more rational and scientific approach, invest in AI to reduce R&D costs and save drug development time, invest in technologies catering to cardiology to boost revenues and accept disease-specific approaches for accurate and timely diagnosis of cancer.

The rising prevalence of cancer and cardiovascular diseases is expected to drive demand for the radiopharmaceuticals market. Radiopharmaceuticals are becoming a safe and effective therapeutic option compared to conventional medicines, offering advantages such as targeted therapy that benefits radiologists in treating these conditions. Cancer is recognized as the second leading cause of death globally, accounting for approximately 1 in 6 deaths. For instance, in April 2024, the International Agency for Research on Cancer (IARC), a France-based specialized agency, reported that in 2022, nearly 20 million new cancer cases and 9.7 million cancer-related deaths occurred worldwide. By 2040, these figures are projected to rise to 29.9 million new cases and 15.3 million deaths annually.

The radiopharmaceuticals market is anticipated to experience significant growth, driven by the increasing demand for personalized medicine. Personalized medicine, also known as precision medicine, is an innovative approach to medical care that tailors medical decisions, treatments, interventions, and drug therapies to the unique characteristics of each patient. Integrating personalized medicine into radiopharmaceuticals enhances the precision and accuracy of imaging and therapy, enabling healthcare providers to deliver more targeted and effective care. For example, in 2022, the Food and Drug Administration's Center for Drug Evaluation and Research (CDER) approved 37 new molecular entities (NMEs), with approximately 34%, or 12 of them, classified as personalized medicines by the Personalized Medicine Coalition (PMC). The increasing demand for personalized medicine is thus a driving force behind the growth of the radiopharmaceuticals market.

Several companies in the radiopharmaceuticals market are adopting strategic initiatives such as opening new manufacturing facilities and expanding plant capacity, gaining significant popularity. ITM Isotopen Technologien Munchen AG (ITM), for instance, launched a new manufacturing facility in the Munich area to increase the production capacity of high-purity (n.c.a.) Lutetium-177 and no-carrier-added (n.c.a.) Lutetium-177-containing radiopharmaceuticals. This move aims to meet the high demand for quality medical isotopes for precision oncology worldwide.

Major players in the radiopharmaceuticals market are forming partnerships to enhance their market profitability. In June 2023, the University of Pittsburgh Medical Center partnered with PharmaLogic Holdings Corporation to produce new radiopharmaceuticals at a Pittsburgh facility. This collaboration enables patients and professionals in the UPMC vicinity to access innovative diagnostic and therapeutic drugs that are not currently available. The non-exclusive agreement outlines the conversion of experimental radiopharmaceuticals into therapeutically useful medications.

In January 2024, Eli Lilly, a US-based pharmaceutical company, completed its acquisition of Point Biopharma for approximately $1.4 billion. This acquisition aligns with Lilly's strategy to enhance its capabilities in the emerging field of radioligand therapies, which aim to make significant advancements in cancer treatment. Point Biopharma specializes in radiopharmaceuticals, complementing Lilly's existing oncology portfolio and promising to improve patient outcomes. Point Biopharma is a US-based company focused on developing targeted radioligand therapies for various cancers.

Major companies operating in the radiopharmaceuticals market include Cardinal Health, Curium Pharma, Siemens Healthineers AG, Novartis AG, General Electric Company (GE), IBA Group, Bayer AG, Lantheus Medical Imaging Inc., Bracco Imaging S.p.A., Eckert & Ziegler, Nihon Medi-Physics Co. Ltd., Fujifilm Corporation, ANSTO, Yantai Dongcheng Pharmaceutical Group Co. Ltd., Bracco Imaging SpA., Canon Inc., China Isotope & Radiation Corporation (CIRC), Alliance Medical, Advanced Accelerator Applications, JSC Isotope, Pharm-Sintez, Synektik SA, Polatom, RadioMedic sro, UJV Rez, Actinium Pharmaceuticals Inc., Alseres Pharmaceuticals Inc., Avid Radiopharmaceuticals, Fusion Pharmaceuticals, Peregrine Pharmaceuticals Inc., PETNET Solutions Inc., Positron Corporation, Triad Isotopes Inc., Telix Pharmaceuticals, Rosatom, Alliance Medical Group, Hologic Inc., Segami Corporation, Eczacybapy-Monrol Nuclear Products, NTP Radioisotopes.

North America was the largest region in the global radiopharmaceuticals market in 2024. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the radiopharmaceuticals market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the radiopharmaceuticals market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The radiopharmaceuticals market consists of sales of technetium disofenin, technetium lidofenin, and technetium mebrofenin. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Radiopharmaceuticals Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on radiopharmaceuticals market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for radiopharmaceuticals ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The radiopharmaceuticals market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Diagnostic, Therapeutic
• 2) By Application: Oncology, Cardiology, Gastroenterology, Neuroendocrinology, Musculoskeletal, Respiratory, Nephrology, Other Applications
• 3) By End User: Hospitals And Ambulatory Surgical Centers, Diagnostic Centers, Cancer Research Institutes
• Subsegments:
• 1) By Diagnostic: Positron Emission Tomography (PET) Radiopharmaceuticals; Single Photon Emission Computed Tomography (SPECT) Radiopharmaceuticals
• 2) By Therapeutic: Alpha Emitters; Beta Emitters; Brachytherapy
• Companies Mentioned: Cardinal Health; Curium Pharma; Siemens Healthineers AG; Novartis AG; General Electric Company (GE)
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Radiopharmaceuticals Market Characteristics

3. Radiopharmaceuticals Market Trends And Strategies

4. Radiopharmaceuticals Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Radiopharmaceuticals Growth Analysis And Strategic Analysis Framework

• 5.1. Global Radiopharmaceuticals PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Radiopharmaceuticals Market Growth Rate Analysis
• 5.4. Global Radiopharmaceuticals Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Radiopharmaceuticals Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Radiopharmaceuticals Total Addressable Market (TAM)

6. Radiopharmaceuticals Market Segmentation

• 6.1. Global Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Diagnostic
• Therapeutic
• 6.2. Global Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oncology
• Cardiology
• Gastroenterology
• Neuroendocrinology
• Musculoskeletal
• Respiratory
• Nephrology
• Other Applications
• 6.3. Global Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals And Ambulatory Surgical Centers
• Diagnostic Centers
• Cancer Research Institutes
• 6.4. Global Radiopharmaceuticals Market, Sub-Segmentation Of Diagnostic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Positron Emission Tomography (PET) Radiopharmaceuticals
• Single Photon Emission Computed Tomography (SPECT) Radiopharmaceuticals
• 6.5. Global Radiopharmaceuticals Market, Sub-Segmentation Of Therapeutic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Alpha Emitters
• Beta Emitters
• Brachytherapy

7. Radiopharmaceuticals Market Regional And Country Analysis

• 7.1. Global Radiopharmaceuticals Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Radiopharmaceuticals Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Radiopharmaceuticals Market

• 8.1. Asia-Pacific Radiopharmaceuticals Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Radiopharmaceuticals Market

• 9.1. China Radiopharmaceuticals Market Overview
• 9.2. China Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Radiopharmaceuticals Market

• 10.1. India Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Radiopharmaceuticals Market

• 11.1. Japan Radiopharmaceuticals Market Overview
• 11.2. Japan Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Radiopharmaceuticals Market

• 12.1. Australia Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Radiopharmaceuticals Market

• 13.1. Indonesia Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Radiopharmaceuticals Market

• 14.1. South Korea Radiopharmaceuticals Market Overview
• 14.2. South Korea Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Radiopharmaceuticals Market

• 15.1. Western Europe Radiopharmaceuticals Market Overview
• 15.2. Western Europe Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Radiopharmaceuticals Market

• 16.1. UK Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Radiopharmaceuticals Market

• 17.1. Germany Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Radiopharmaceuticals Market

• 18.1. France Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Radiopharmaceuticals Market

• 19.1. Italy Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Radiopharmaceuticals Market

• 20.1. Spain Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Radiopharmaceuticals Market

• 21.1. Eastern Europe Radiopharmaceuticals Market Overview
• 21.2. Eastern Europe Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Radiopharmaceuticals Market

• 22.1. Russia Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Radiopharmaceuticals Market

• 23.1. North America Radiopharmaceuticals Market Overview
• 23.2. North America Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Radiopharmaceuticals Market

• 24.1. USA Radiopharmaceuticals Market Overview
• 24.2. USA Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Radiopharmaceuticals Market

• 25.1. Canada Radiopharmaceuticals Market Overview
• 25.2. Canada Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Radiopharmaceuticals Market

• 26.1. South America Radiopharmaceuticals Market Overview
• 26.2. South America Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Radiopharmaceuticals Market

• 27.1. Brazil Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Radiopharmaceuticals Market

• 28.1. Middle East Radiopharmaceuticals Market Overview
• 28.2. Middle East Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Radiopharmaceuticals Market

• 29.1. Africa Radiopharmaceuticals Market Overview
• 29.2. Africa Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Radiopharmaceuticals Market Competitive Landscape And Company Profiles

• 30.1. Radiopharmaceuticals Market Competitive Landscape
• 30.2. Radiopharmaceuticals Market Company Profiles
  • 30.2.1. Cardinal Health Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Curium Pharma Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. General Electric Company (GE) Overview, Products and Services, Strategy and Financial Analysis

31. Radiopharmaceuticals Market Other Major And Innovative Companies

• 31.1. IBA Group
• 31.2. Bayer AG
• 31.3. Lantheus Medical Imaging Inc.
• 31.4. Bracco Imaging S.p.A.
• 31.5. Eckert & Ziegler
• 31.6. Nihon Medi-Physics Co. Ltd.
• 31.7. Fujifilm Corporation
• 31.8. ANSTO
• 31.9. Yantai Dongcheng Pharmaceutical Group Co. Ltd.
• 31.10. Bracco Imaging SpA.
• 31.11. Canon Inc.
• 31.12. China Isotope & Radiation Corporation (CIRC)
• 31.13. Alliance Medical
• 31.14. Advanced Accelerator Applications
• 31.15. JSC Isotope

32. Global Radiopharmaceuticals Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Radiopharmaceuticals Market

34. Recent Developments In The Radiopharmaceuticals Market

35. Radiopharmaceuticals Market High Potential Countries, Segments and Strategies

• 35.1 Radiopharmaceuticals Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Radiopharmaceuticals Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Radiopharmaceuticals Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer